Angelos M. Stergiou

Biography

Dr. Angelos M. Stergiou, founder, CEO & Vice Chairman of the Board of SELLAS Life Sciences Group, Ltd. has held international positions of increasing responsibility in pharmaceuticals and biotechnology companies over the past 15 years, including PAION AG, Accentia Biopharmaceuticals, BioVest International, Analytica International, Anavex Life Sciences. He also co-founded a boutique NY-based health economics and pricing-reimbursement and health access company, Genesis Life Sciences (Genesis Research) prior to founding Sellas. Dr. Stergiou has held specific roles ranging from Head of Clinical Research and Vice President of Product Development, Chief Medical Officer and Chief Operations Officer with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, manufacturing and controls (CMC). Dr. Stergiou has led and overseen research endeavors in all phases of clinical development across many indications, including Central Nervous System, cardiovascular, oncology, respiratory and autoimmune diseases, and has a broad understanding of all aspects of clinical development and medical affairs. He has designed and implemented research projects in the United States, Canada, Australia, Japan and Europe. He has had numerous interactions with the FDA, EMEA and EU health authorities in addition to regulatory exposure in Australia and Japan. Dr. Stergiou was part of the joint steering and oversight committee in the license deal of Paion’s desmoteplase drug with Forest Labs and part of senior management of Accentia Biopharmaceuticals and Biovest International. He also led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, into completion which was presented at the American Society of Clinical Oncology plenary session in 2009 and also holds a patent on the technology. Dr. Stergiou holds a Doctor of Medicine and a Doctor of Science (honoris causa) degree from Kentucky Wesleyan College and US American Institute of Medicine, and received his Bachelor of Sciences degree from Kentucky Wesleyan College with a major in Pre-Medicine, Biology and Chemistry. Dr. Stergiou is a member of the Board of Trustees at Kentucky Wesleyan College and a Fellow of the Royal Society of Medicine (UK – ID:00707077), an active member of the World Medical Association, and a member of the American Academy of Physicians in Clinical Research and the Association of Clinical Research Professionals. He is a frequent guest lecturer/speaker for global clinical development and clinical research and regulatory matters, he has presented to audiences at conferences and lectured at post-secondary institutions including Columbia University, and numerous European universities. He is fluent in English, German and Greek. Dr. Angelos M. Stergiou, founder, CEO & Vice Chairman of the Board of SELLAS Life Sciences Group, Ltd. has held international positions of increasing responsibility in pharmaceuticals and biotechnology companies over the past 15 years, including PAION AG, Accentia Biopharmaceuticals, BioVest International, Analytica International, Anavex Life Sciences. He also co-founded a boutique NY-based health economics and pricing-reimbursement and health access company, Genesis Life Sciences (Genesis Research) prior to founding Sellas. Dr. Stergiou has held specific roles ranging from Head of Clinical Research and Vice President of Product Development, Chief Medical Officer and Chief Operations Officer with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, manufacturing and controls (CMC). Dr. Stergiou has led and overseen research endeavors in all phases of clinical development across many indications, including Central Nervous System, cardiovascular, oncology, respiratory and autoimmune diseases, and has a broad understanding of all aspects of clinical development and medical affairs. He has designed and implemented research projects in the United States, Canada, Australia, Japan and Europe. He has had numerous interactions with the FDA, EMEA and EU health authorities in addition to regulatory exposure in Australia and Japan. Dr. Stergiou was part of the joint steering and oversight committee in the license deal of Paion’s desmoteplase drug with Forest Labs and part of senior management of Accentia Biopharmaceuticals and Biovest International. He also led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, into completion which was presented at the American Society of Clinical Oncology plenary session in 2009 and also holds a patent on the technology. Dr. Stergiou holds a Doctor of Medicine and a Doctor of Science (honoris causa) degree from Kentucky Wesleyan College and US American Institute of Medicine, and received his Bachelor of Sciences degree from Kentucky Wesleyan College with a major in Pre-Medicine, Biology and Chemistry. Dr. Stergiou is a member of the Board of Trustees at Kentucky Wesleyan College and a Fellow of the Royal Society of Medicine (UK – ID:00707077), an active member of the World Medical Association, and a member of the American Academy of Physicians in Clinical Research and the Association of Clinical Research Professionals. He is a frequent guest lecturer/speaker for global clinical development and clinical research and regulatory matters, he has presented to audiences at conferences and lectured at post-secondary institutions including Columbia University, and numerous European universities. He is fluent in English, German and Greek.

Research Interest

Pharmaceutical Sciences